Jamshedpur Reporter

Ischemic Stroke Pipeline, Clinical Trials Analysis, FDA Approvals and Emerging Drugs 2023 | Major Companies – Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, and Others

 Breaking News
  • No posts were found

Ischemic Stroke Pipeline, Clinical Trials Analysis, FDA Approvals and Emerging Drugs 2023 | Major Companies – Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, and Others

May 18
03:10 2023
Ischemic Stroke Pipeline, Clinical Trials Analysis, FDA Approvals and Emerging Drugs 2023 | Major Companies - Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, and Others

DelveInsight’s, “Ischemic Stroke Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including Ischemic Stroke clinical trials and nonclinical stage products. It also covers the Ischemic Stroke therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Ischemic Stroke Pipeline Report

 

  • In July 2022, ACTICOR BIOTECH announced that it had received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.This status allowed Acticor Biotech to strengthen interactions and obtain early dialogues with regulatory authorities in order to confirm the clinical development plan for glenzocimab in the treatment of stroke.

 

  • In July 2022, NervGen Pharma announced the University of Cincinnati and Case Western Reserve University (CWRU) had published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was initiated up to 7 days after onset.

 

  • In June 2022, Pharmazz Inc released positive topline results for its Phase III clinical trial that evaluated sovateltide as a treatment for acute ischemic stroke.The findings showed that, at 90 days, the modified Rankin Score (mRS) had a significantly greater number of individuals with an improvement of 2 points or greater on mRS, mRS with a significant median score reduction, and a significantly greater reduction of individuals with an improvement of 6 or more points on the NIHSS Level of Consciousness (1A)

 

  • In February 2022, Acticor Biotech reported positive data from its Phase Ib/IIa ACTIMIS clinical trial of glenzocimab analyzed as an add-on treatment to standard of care for acute ischemic stroke (AIS) patients.Findings showed that the trial met the primary endpoint, establishing the favourable safety profile of glenzocimab.

 

  • In February 2022, Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke.

 

  • In May 2022, Athersys, Inc. announced that its partner, HEALIOS K.K. (Healios), had reported topline results for its Japan ischemic stroke study, TREASURE.Improvement in pre-specified measures of functional “independence” and good outcomes, were found such as mRS ≤2, Barthel Index ≥95 and Global Recovery, associated with MultiStem treatment. The primary endpoint, excellent outcome at 90 days, did not reach statistical significance in the population. No material differences in safety outcomes, including mortality and life-threatening adverse events between the treatment and placebo groups were noticed.

 

Request a sample and discover the recent breakthroughs happening in the Ischemic Stroke Pipeline Landscape @ Ischemic Stroke Pipeline Outlook

 

Ischemic Stroke Overview

Stroke is a leading cause of death and disability worldwide and can be broadly classified into ischaemic stroke and haemorrhagic stroke, the latter of which includes intracerebral haemorrhage and subarachnoid haemorrhage. Ischaemic stroke is defined as infarction of the brain, spinal cord or retina1 and represents ~71% of all strokes globally.

 

Key Takeaways from the Ischemic Stroke Pipeline Report

 

  • DelveInsight’s ischemic stroke pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Ischemic Stroke treatment.

 

  • The Leading ischemic stroke companies include Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz, and others 

 

  • Promising ischemic stroke pipeline therapies include MultiStem, Elezanumab, LT3001, AP-188, 3K3A-APC, NIN-S119, RNS60, PP 007, Glenzocimab, SB-623, AVLX-144, BIIB 131, Conestat alfa, NCS-01, Nerinetide, UMC119-06, SY-007, Edaravone, TB006, Neu2000, Balovaptan, DM 199, ApTOLL, BMS-986177, NanO2, Tenecteplase, SIM1910-09, UMSC01, Prourokinase recombinant,  Sovateltide, and others.

 

  • The Ischemic Stroke Companies and academics that are working to assess challenges and seek opportunities that could influence Ischemic Stroke R&D. The Ischemic Stroke pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Find out more about the Ischemic Stroke Diagnosis and Treatment of patients @ Ischemic Stroke Ongoing Clinical Trials Analysis

 

Ischemic Stroke Emerging Drugs Profile

 

  • 3K3A-APC: ZZ Biotech

3K3A-APC, is a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. 3K3A-APC was designed to enhance the cytoprotective and anti-inflammatory activities of APC while greatly reducing its anti-coagulant activity. APC is a protease possessing two distinct functions: 1) anticoagulant properties mediated by proteolysis of coagulation factors Va and VIIIa, and 2) cytoprotective effects including anti-apoptotic effects, anti-inflammatory effects, and endothelial barrier stabilization. ZZ Biotech has completed RHAPSODY, a multicenter Phase II clinical trial of its experimental drug, 3K3A-APC and is in Phase III for the treatment of patients suffering from acute ischemic stroke. This study was supported by the National Institutes of Health through a pair of NeuroNEXT grants.

  • BMS-986177: Bristol-Myers Squibb

BMS-986177 (Factor XIa) is an investigational anticoagulant compound. Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway. A small study of Hemophilia C patients showed a lower risk of stroke. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke and Transient Ischemic Attack (TIA).

 

  • XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.

XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03-EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose-dependent way. Mechanistically, XY03-EA inhibited ROS-dependent autophagy activation and thereby protected the PC-12 cells from the autophagic cell death induced by OGD/R. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

 

  • NONO-42: NoNO Inc.

NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Of the 650,000 people experiencing an acute ischemic stroke treated annually in US hospitals, approximately 10% receive a thrombolytic, which may reduce the applicability of nerinetide. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.

 

Ischemic Stroke Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, ZZ Biotech.

 

Discover more about the list of Ischemic Stroke FDA-approved drugs @ Ischemic Stroke Treatment Landscape

 

Scope of the Ischemic Stroke Pipeline Report

 

  • Coverage- Global

 

  • Ischemic Stroke Companies- Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others

 

  • Ischemic Stroke Pipeline Therapies- MultiStem, Elezanumab, LT3001, AP-188, 3K3A-APC, NIN-S119, RNS60, PP 007, Glenzocimab, SB-623, AVLX-144, BIIB 131, Conestat alfa, NCS-01, Nerinetide, UMC119-06, SY-007, Edaravone, TB006, Neu2000, Balovaptan, DM 199, ApTOLL, BMS-986177, NanO2, Tenecteplase, SIM1910-09, UMSC01, Prourokinase recombinant,  Sovateltide, and others.

 

  • Ischemic Stroke Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for Ischemic Stroke Emerging Therapies and Ongoing Clinical Trials; visit @ Ischemic Stroke Emerging Therapies and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Ischemic Stroke: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Ischemic Stroke – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. MultiStem: Athersys, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Elezanumab: Tarveda Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. AVLX-144: Avilex Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. AP-188: Algernon Pharmaceutical
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Ischemic Stroke Key Companies
  21. Ischemic Stroke Key Products
  22. Ischemic Stroke- Unmet Needs
  23. Ischemic Stroke- Market Drivers and Barriers
  24. Ischemic Stroke- Future Perspectives and Conclusion
  25. Ischemic Stroke Analyst Views
  26. Ischemic Stroke Key Companies
  27. Appendix

 

For further information on the Ischemic Stroke Pipeline therapeutics, reach out to Ischemic Stroke Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/